title: [Provision of information by pharmacists regarding the effective timing of co-administration of first-generation serotonin receptor antagonists and dexamethasone for chemotherapy-induced nausea and vomiting in patients receiving Doxorubicin and cyclophosphamide chemotherapy for breast cancer].
abstract: The combination of doxorubicin and cyclophosphamide is a standard chemotherapy regimen for breast cancer. Nausea and vomiting are two common adverse effects that may lead to a significant deterioration in the patient's quality of life. We report on the provision of information by pharmacists regarding the effective timing of the co-administration of first-generation serotonin receptor antagonists and dexamethasone for nausea and vomiting in patients receiving doxorubicin and cyclophosphamide (AC) chemotherapy for breast cancer. A total of 51 patients were enrolled in this study between January 2009 and December 2009. Vomiting was grade 0 in 34(67%)patients, grade 1 in 13(25%)patients, grade 2 in 3(6%)patients, and grade 3 in 1(2%)patient. Nausea was grade 0 in 17(33%)patients, grade 1 in 13(25%)patients, grade 2 in 13(25%) patients, and grade 3 in 15(29%)patients. The relative risk factors of vomiting were as follows: age, 1. 27; tumor size, 11. 05; node status, 1. 86; and chemotherapy, 0. 409. Only tumor size showed a significant difference(p=0. 006). The results of this study of 34 patients suggest that aprepitant may not be necessary for preventing AC chemotherapy. They showed that the provision of information by pharmacists regarding the effective timing of the co-administration of first-generation serotonin receptor-antagonists and dexamethasone is effective in patients who cannot take aprepitant.
authors.affiliation: Dept. of Pharmacy, Kyorin University Hospital.
authors.forename: Hisanaga
authors.initials: H
authors.lastname: Nomura
authors.forename: Hideyasu
authors.initials: H
authors.lastname: Kawakami
authors.forename: Hisanori
authors.initials: H
authors.lastname: Shimizu
authors.forename: Kentaro
authors.initials: K
authors.lastname: Imi
authors.forename: Hiroki
authors.initials: H
authors.lastname: Ito
authors.forename: Hirotsugu
authors.initials: H
authors.lastname: Isaka
authors.forename: Takao
authors.initials: T
authors.lastname: Shinohara
authors.forename: Shigeru
authors.initials: S
authors.lastname: Nagai
authors.forename: Shigeru
authors.initials: S
authors.lastname: Imoto
mesh_terms: D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000008:administration & dosage* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003907:Dexamethasone / Q000008:administration & dosage* / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D009325:Nausea / Q000517:prevention & control*; D009367:Neoplasm Staging; D010595:Pharmacists; D012702:Serotonin Antagonists / Q000008:administration & dosage* / Q000627:therapeutic use; D014839:Vomiting / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D012702:Serotonin Antagonists; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide